Literature DB >> 22398067

Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients.

Ulf Helwig1, Michael Müller, Jürgen Hedderich, Stefan Schreiber.   

Abstract

INTRODUCTION: Latent tuberculosis infection is detected by the tuberculin skin test before treating with anti-Tumour-Necrosis factor alpha (anti TNFα) reagents. More accurate are Interferon gamma release assays (IFNγ release assays) to identify patients with latent tuberculosis. Because of a positive control in this assay, it is possible to identify those patients in which a result of tuberculosis testing is not available due to a lack of stimulation capacity of lymphocytes (indeterminate result). Patients suffering from IBD are often treated with immunosuppressive agents, which may influence the results of tuberculosis testing. AIM: The aim is to investigate the influence of immunosuppressive agents on the outcome of IFNγ-release assay.
METHODS: 50 consecutive patients were documented before introducing anti-TNF-treatment in this single centre study between April 2009 and April 2010. Data of INFγ release assay for latent tuberculosis, skin test and laboratory data and current medication were enrolled.
RESULTS: For the period of one year data of 45 consecutive patients was available for statistical analysis. 24 patients out of 45 (corresponding to 53.3%) received at least low doses of corticoid treatment and 27 patients out of 45 (corresponding to 60.0%) received immunosuppressive agents. 13 patients out of 45 (corresponding to 28.9%) had an indeterminate result of the QuantiFERON test. A correlation between the indeterminate result and combination therapy of corticosteroids was found. The concomitant therapy of immunosuppressive agents lead to a lower IFN release but no significance was found.
CONCLUSIONS: Steroid treatment and further combination therapy with immunosuppressive agents lead to a high risk of indeterminate QuantiFERON test.
Copyright © 2011 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22398067     DOI: 10.1016/j.crohns.2011.09.011

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  14 in total

Review 1.  Mycobacterium avium subspecies paratuberculosis in the etiology of Crohn's disease, cause or epiphenomenon?

Authors:  Elisa Liverani; Eleonora Scaioli; Carla Cardamone; Paola Dal Monte; Andrea Belluzzi
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

2.  Indeterminate QuantiFERON-TB Gold Increases Likelihood of Inflammatory Bowel Disease Treatment Delay and Hospitalization.

Authors:  Ravy K Vajravelu; Mark T Osterman; Faten N Aberra; Jason A Roy; Gary R Lichtenstein; Ronac Mamtani; David S Goldberg; James D Lewis; Frank I Scott
Journal:  Inflamm Bowel Dis       Date:  2017-12-19       Impact factor: 5.325

3.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

4.  Dynamic QuantiFERON Response in Psoriasis Patients Taking Long-Term Biologic Therapy.

Authors:  Lorenzo Drago; Lucia Nicola; Valentina Signori; Elisa Palazzi; Cecilia Garutti; Samantha Spadino; Gianfranco Altomare
Journal:  Dermatol Ther (Heidelb)       Date:  2013-02-23

5.  The Significance of Sensitive Interferon Gamma Release Assays for Diagnosis of Latent Tuberculosis Infection in Patients Receiving Tumor Necrosis Factor-α Antagonist Therapy.

Authors:  Yu Jung Jung; Hye In Woo; Kyeongman Jeon; Won-Jung Koh; Dong Kyoung Jang; Hoon Suk Cha; Eun Mi Koh; Nam Yong Lee; Eun-Suk Kang
Journal:  PLoS One       Date:  2015-10-16       Impact factor: 3.240

6.  The conundrum of indeterminate QuantiFERON-TB Gold results before anti-tumor necrosis factor initiation.

Authors:  Shahrad Hakimian; Yevgeniy Popov; Abbas H Rupawala; Karen Salomon-Escoto; Steven Hatch; Randall Pellish
Journal:  Biologics       Date:  2018-02-27

7.  Evaluating an Education Program to Reduce Indeterminate QuantiFERON Gold In-Tube Results.

Authors:  Saroochi Agarwal; Duc T Nguyen; Justin D Lew; Brenda Campbell; Edward A Graviss
Journal:  Tuberc Res Treat       Date:  2018-10-11

8.  Fluctuating Behavior and Influential Factors in the Performance of the QuantiFERON-TB Gold In-Tube Assay in the Diagnosis of Tuberculosis.

Authors:  Lei Bao; Tao Li; Ni Diao; Yaojie Shen; Lingyun Shao; Ying Zhang; Shuihua Lu; Wenhong Zhang
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

Review 9.  The Role of Laboratory Tests in Crohn's Disease.

Authors:  Maria Cappello; Gaetano Cristian Morreale
Journal:  Clin Med Insights Gastroenterol       Date:  2016-08-18

10.  Immune-mediated inflammatory diseases differently affect IGRAs' accuracy for latent tuberculosis infection diagnosis in clinical practice.

Authors:  Irene Latorre; Sonia Mínguez; José-Manuel Carrascosa; Juan Naves; Raquel Villar-Hernández; Beatriz Muriel; Cristina Prat; Esther García-García; Irma Casas; Eugeni Domènech; Carlos Ferrándiz; Lourdes Mateo; Jose Domínguez
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.